Levagen+ for symptoms of diabetic peripheral neuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 randomized, placebo-controlled trial tests whether daily Levagen+ reduces symptoms of diabetic peripheral neuropathy in adults. Eligible participants aged 18–75 with type 1 or type 2 diabetes on stable glucose-lowering therapy and an S-LANSS score of 12 or more will be randomized to receive Levagen+ or matching placebo for 12 weeks. Participants will have remote visits every three weeks and attend a local pathology centre for blood draws at baseline and follow-up. Symptom changes and safety measures will be monitored to determine whether Levagen+ offers a measurable benefit over placebo.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18-75 years.
* Using prescribed glucose-lowering medications, including oral medications (stable dose for 3 months or more) and/or insulin for diabetes (type 1 or 2).
* Scoring12 or more on the Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS).
* Able to provide informed consent.
* Agree not to change current diet and/or exercise frequency or intensity during entire enrolment period.
* Agree to not participate in another clinical trial during the study period.
* Able to attend an ACL collection centre.

Exclusion Criteria:

* Peripheral neuropathy due to causes other than diabetes mellitus (e.g. nutritional deficiencies; hereditary sensory neuropathy; paraneoplastic diseases; advanced liver disease; kidney disease; hypothyroidism; prolonged phenytoin, warfarin or immunosuppressive drug use; active infection \[HIV, Lyme disease, Epstein-Barr virus, Hepatitis C, Shingles, Leprosy\]; autoimmune disease \[Sjogren syndrome, Lupus, Rheumatoid arthritis, Guillain-Barre syndrome\]; trauma / injury; toxins \[heavy metals, chemicals\]; antibiotics; or inflammatory conditions \[vasculitis\]).
* Serious illness e.g., paraneoplastic diseases, advanced liver disease, kidney disease, hypothyroidism, mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, or heart conditions, or peripheral vascular disease
* Unstable illness e.g., diabetes and thyroid gland dysfunction, hypercholesterolemia
* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.
* Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin
* Herbal medicines for pain relief including, but not limited to, medicinal cannabis, willow bark (Salix alba), Boswellia (Boswellia serrata) or turmeric/curcumin (Curcuma longa).
* Active smokers, nicotine use or drug (prescription or illegal substances) abuse.
* Chronic past and/or current alcohol use (\>14 alcoholic drinks per week)
* Females attempting to conceive, pregnant or lactating
* Allergic, sensitive or intolerant to any of the ingredients in active or placebo formula.
* Difficulty swallowing capsules.
* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month.
* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.

Where it's running

• RDC Clinical
  Fortitude Valley, Queensland, Australia Recruiting

Study contacts

• Study coordinator: Amanda Rao
• Email: research@rdcglobal.com.au
• Phone: +61(0)731024486

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of perturbation-based balance training vs conventional balance training for reactive stepping in adults with diabetic nerve damage

  A 40-person study will test whether adding perturbation-based balance training helps adults with diabetic peripheral neuropathy react better to balance threats compared with standard balance training.

  Recruiting Lahore University of Biological and Applied Sciences · Lahore, Punjab Province · NCT07902297

• Ultrasound-guided nerve hydrodissection for diabetic leg nerves

  A single ultrasound-guided nerve hydrodissection procedure is tested to see if it helps people with diabetic lower limb entrapment neuropathy feel less pain and have better nerve function.

  Recruiting Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07625020

• Shortwave therapy for diabetic peripheral neuropathy

  A one-center study will test whether shortwave therapy given for five days can improve nerve symptoms in adults with diabetic neuropathy compared to a sham treatment.

  Recruiting Chongqing Medical University · Chongqing · NCT07625007

• MinION sequencing to identify microbes in diabetic foot bone infections

  This study will test a rapid MinION DNA sequencing method to identify bacteria, fungi, and resistance genes in infected diabetic foot wounds and compare the results with standard culture.

  Recruiting Centre Hospitalier Universitaire de Nīmes · Nîmes, Gard · NCT07391995

• Intraneural Facilitation and Otago Exercise for Diabetic Peripheral Neuropathy

  This study will test whether intraneural facilitation, the Otago exercise program, or a combination of both can improve balance, reduce neuropathic pain, and improve quality of life for people aged 50–75 with diabetic peripheral neuropathy.

  Recruiting Riphah International University · Lahore, Punjab Province · NCT07274735

• Topical Capsadyn (palmitated capsaicin) for diabetic neuropathic foot pain

  This study will test whether a topical Capsadyn cream can reduce foot pain in adults with diabetic peripheral neuropathy.

  Recruiting Early Phase 1 Carilion Clinic · Roanoke, Virginia · NCT07260656

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.